| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458104 | MISSION PHARMACAL CO | NA |
Nov, 2038
(15 years from now) | |
Thiola Ec is owned by Mission Pharmacal Co.
Thiola Ec contains Tiopronin.
Thiola Ec has a total of 1 drug patent out of which 0 drug patents have expired.
Thiola Ec was authorised for market use on 28 June, 2019.
Thiola Ec is available in tablet, delayed release;oral dosage forms.
Thiola Ec can be used as a method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria.
The generics of Thiola Ec are possible to be released after 14 November, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Jun 28, 2026 |
Drugs and Companies using TIOPRONIN ingredient
Market Authorisation Date: 28 June, 2019
Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria
Dosage: TABLET, DELAYED RELEASE;ORAL
THIOLA EC family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic